HARROW, INC. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Harrow completed its acquisition of TYRVAYA (varenicline nasal spray for dry eye disease) from Viatris Inc. on October 5, 2026. Harrow paid $30 million upfront in cash and may pay up to $70 million in contingent milestone payments based on TYRVAYA net sales, for total potential consideration of $100 million. The deal includes worldwide rights except Japan; Viatris retains Japan rights and will pay royalties. Approximately 40 Viatris personnel will join Harrow's Ocular Surface team. Harrow expects TYRVAYA to contribute >$30 million in revenue in 2027.
Why this rating
Meaningful acquisition adding established FDA-approved product to ~$1B company; $30M cash outlay is ~3% of market cap, milestone payments contingent. Adds 40 employees, revenue contribution ~$30M+ in 2027. Real but not transformational; significant portfolio diversification in core dry eye market.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.